Drug Profile
SIM 916
Latest Information Update: 21 Jan 2005
Price :
$50
*
At a glance
- Originator Wyeth
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Estrogen receptor agonists; NF-kappa B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 10 Jan 2005 Discontinued - Phase-I for Rheumatoid arthritis in USA (PO)
- 24 Jun 2004 Phase-I clinical trials in Rheumatoid arthritis in USA (PO)
- 31 Dec 2002 Preclinical development for Rheumatoid arthritis in USA (PO)